EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A cap-dependent endonuclease inhibitor acts as a potent antiviral agent against La Crosse virus infection

Kei Konishi iD, Yoshiyuki Taoda, Manabu Igarashi, Takao Shishido, Kazuya Yasuo, William W Hall, Yasuko Orba, Hirofumi Sawa, Michihito Sasaki iD, Akihiko Sato iD

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.00186-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Kei Konishi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Drug Discovery & Disease Research, Shionogi & Co., Ltd., Osaka, Japan. Hauptthemen laut MEDLINE: Antiviral Agents, La Crosse virus, Encephalitis, California, Pyridones. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Science and Technology Agency, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

La Crosse virus (LACV) infection, the causative agent of La Crosse encephalitis, can lead to severe neurological symptoms and sequelae, particularly in children. Despite annual reports of neurologically symptomatic cases, no effective treatment has yet been established. Bunyaviruses, including LACV, utilize a cap-snatching mechanism for transcription, with a cap-dependent endonuclease (CEN) serving as a promising target for antiviral treatment. Specifically, we now demonstrate that a CEN inhibitor, carbamoyl pyridone carboxylic acid (CAPCA)-1, exhibits potent anti-LACV activity in vitro and in vivo . CAPCA-1 exhibited 50% effective concentration values below 1 µM in neuronal and non-neuronal cells, demonstrating a higher in vitro activity than the nucleoside analogs, ribavirin and favipiravir. Multiple passages of LACV in the presence of CAPCA-1 produced numerous amino acid mutations in the CEN active site. Notably, using a lethal infection model in mice, CAPCA-1 treatment reduced viral loads in the brain and extended the survival rate of LACV-infected mice. These findings highlight the potential of CEN inhibitors as treatment options for La Crosse encephalitis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsLa Crosse virusEncephalitis, CaliforniaPyridonesEndonucleasesEnzyme InhibitorsAnimalsMiceHumansPyrazinesViral LoadAmidesVero CellsRibavirinVirus ReplicationChlorocebus aethiops

Stichwörter der Autor:innen

La Crosse virusantiviralsbunyavirusescap-dependent endonuclease

Substanzen

Antiviral AgentsPyridonesEndonucleasesPyrazinesfavipiravirEnzyme InhibitorsAmidesRibavirin

Autor:innen und Institutionen

  • Laboratory for Drug Discovery & Disease Research, Shionogi & Co., Ltd., Osaka, Japan.
  • Division of Anti-Virus Drug Research, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • Laboratory for Medicinal Chemistry Research, Shionogi & Co., Ltd., Osaka, Japan.
  • Division of Global Epidemiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • National Virus Reference Laboratory, School of Medicine, University College Dublin, Dublin, Ireland.

ORCID-Profile: Kei Konishi, Michihito Sasaki, Akihiko Sato

Förderung

  • Japan Science and Technology Agency
  • Japan Agency for Medical Research and Development

Zitieren

APA

Konishi, K., Taoda, Y., Igarashi, M., Shishido, T., Yasuo, K., Hall, W. W., Orba, Y., Sawa, H., Sasaki, M., & Sato, A. (2025). A cap-dependent endonuclease inhibitor acts as a potent antiviral agent against La Crosse virus infection. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00186-25

Vancouver

Konishi K, Taoda Y, Igarashi M, Shishido T, Yasuo K, Hall WW, et al. A cap-dependent endonuclease inhibitor acts as a potent antiviral agent against La Crosse virus infection. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00186-25

BibTeX
@article{Konishi2025,
  author = {Konishi, Kei and Taoda, Yoshiyuki and Igarashi, Manabu and Shishido, Takao and Yasuo, Kazuya and Hall, William W and Orba, Yasuko and Sawa, Hirofumi and Sasaki, Michihito and Sato, Akihiko},
  title = {A cap-dependent endonuclease inhibitor acts as a potent antiviral agent against La Crosse virus infection},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.00186-25}
}
Kostenlos starten →